AGIO

Agios Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website agios.com
Employees(FY) 389
ISIN US00847X1046

Performance

-7.2%

-34.9%

-25.24%

-16.78%

+59.05%

YTD

+53.6%

Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Advanced Technical Analysis

Technical Analysis of AGIO 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score of 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of AGIO

Stock Rank

Recent News & Updates

2024-12-18 07:53
Agios Pharmaceuticals Says Mitapivat Granted EU Orphan Drug Status for Sickle Cell Disease(MT Newswires)
2024-12-18 07:00
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease(GlobeNewswire)
2024-12-17 18:00
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease(Globenewswire)
2024-12-10 10:46
Here's Why Agios Stock Plummeted More Than 20% on Monday(Zacks)
2024-12-10 09:39
Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank(TipRanks)
2024-12-10 07:12
RBC Raises Price Target on Agios Pharmaceuticals to $57 From $55, Keeps Outperform Rating(MT Newswires)
2024-12-09 16:21
Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug(Investor's Business Daily)
2024-12-09 04:38
Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals(MT Newswires)
2024-12-08 12:40
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat(GlobeNewswire)
2024-12-07 23:40
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat(Globenewswire)
2024-12-06 11:31
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?(Zacks)
2024-12-05 08:42
Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?(Zacks)
2024-12-05 05:00
Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios(Zacks)
2024-12-04 09:42
4 Medical Product Stocks to Buy From a Prospective Industry(Zacks)
2024-11-26 09:40
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?(Zacks)
2024-11-07 06:57
Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News(Simply Wall St.)
2024-11-05 09:05
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition(GlobeNewswire)
2024-11-04 20:05
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition(Globenewswire)
2024-11-01 10:47
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down(Zacks)
2024-11-01 09:40
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?(Zacks)
2024-11-01 08:57
Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag(Simply Wall St.)
2024-11-01 03:03
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...(GuruFocus.com)
2024-10-31 10:34
Agios Pharmaceuticals Shares Fall After Q3 Revenue Miss(MT Newswires)
2024-10-31 06:42
Agios Pharmaceuticals: Q3 Earnings Snapshot(Associated Press Finance)
2024-10-31 06:30
Agios Reports Business Highlights and Third Quarter 2024 Financial Results(GlobeNewswire)
2024-10-30 19:45
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates(Yahoo Finance)
2024-10-30 18:30
Agios Reports Business Highlights and Third Quarter 2024 Financial Results(Globenewswire)
2024-10-23 07:00
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease(GlobeNewswire)
2024-10-22 19:00
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease(Globenewswire)
2024-10-17 07:00
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024(GlobeNewswire)

Page 1 of 10

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.